Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyWellfleet PRP Injections Coverage Policy | OpenPay…
    Ask Trek AI about this page
    CurrentWellfleetPolicy GL-019

    Platelet-Rich Plasma Injections

    Customize your policy alerts

    Sign up for wellfleet Policy GL-019 alerts

    Get alerted when Policy GL-019 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This payment guideline describes how Wellfleet evaluates platelet-rich plasma utilization before payment for applicable commercial and student health plans, including criteria for nursing review, physician review, and experimental or investigational determinations.

    Policy Summary
    PayerWellfleet
    PolicyPlatelet-Rich Plasma Injections
    Policy CodePolicy GL-019
    Change TypeNo material change
    Effective DateNov 1, 2025
    Next Review DateSep 1, 2026
    Key ActionSubmit PRP claims under codes 0232T, G0460, G0465, or P9020 for evaluation before payment.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Codes subject to evaluation before payment
    3Evaluation outcomes
    E/IExperimental or investigational utilization
    ReviewUnlisted utilization

    Coverage Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Diagnosis- and procedure-specific utilization grid

    The guideline grid evaluates each diagnosis or procedure as supporting information, approval after RN review, referral for physician review, or experimental, investigational, or unproven utilization.

    Approved after RN review

    • Ankle injections for osteoarthritis — the applicable grid entry is marked approved after RN review; the grid also contains a separate experimental/investigational entry for ankle injections.

      Supporting information includes mixed study results, including a randomized trial showing no significant improvement versus placebo and inconsistent evidence across studies.

    • Anterior cruciate ligament injury or reconstruction without surgery — approved after RN review.

      Supporting information describes positive results for injection without surgery.

    • Surgical ACL reconstruction patellar tendon donor-site enlargement — approved after RN review.

      Supporting information states that PRP application at the harvest site contributed to improved healing and pain.

    • Meniscal tears with repair — approved after RN review.

      Supporting information states that a systematic review suggested PRP can enhance arthroscopic repair and reduce failure rates, pain severity, and improve range of motion.

    • Rotator cuff tendinopathy or partial tears — approved after RN review.

      Supporting information describes PRP as a viable conservative alternative to corticosteroid injection for rotator cuff disease, with evidence of comparable or improved pain and functional outcomes.

    • Ulnar collateral ligament injury — approved after RN review.

      Supporting information includes three small athlete studies reporting improved outcomes.

    Refer for physician review

    • Knee injections for osteoarthritis — referred for physician review.

      The grid cites evidence from the RESTORE randomized clinical trial and related studies.

    • Lateral epicondylitis without LR-PRP — referred for physician review.

      Evidence is inconsistent across varied controls and treatment arms.

    • Muscle injury — referred for physician review.

      Non-randomized studies reported improved tissue repair or accelerated recovery, while randomized trials had controversial results.

    • Patellar tendinopathy — referred for physician review.

      Studies report minimal benefit or conflicting information.

    • Plantar fasciitis where the grid marks referral — referred for physician review.

      Reviews describe conflicting, low-quality evidence and only marginal or limited benefit.

    Experimental, investigational, or unproven

    • Achilles tendinopathy — experimental, investigational, or unproven.

      Randomized controlled trials failed to show superiority of PRP compared with placebo or physiotherapy.

    • Achilles rupture — experimental, investigational, or unproven.

      The supporting information states that surgical treatment is required.

    • Surgical ACL injury or reconstruction — experimental, investigational, or unproven.

      Systematic reviews found no beneficial clinical, bone-graft integration, or bony-tunnel-prevention effects when PRP is used intraoperatively.

    • Ankle injections for osteoarthritis where the grid marks the experimental/investigational entry — experimental, investigational, or unproven.

      The cited evidence includes a randomized trial showing no significant improvement versus placebo and limitations such as small sample sizes and lack of a standardized PRP formulation.

    Lateral epicondylitis formulation-specific review

    Lateral epicondylitis utilization is differentiated by PRP formulation.

    Lateral epicondylitis with LR-PRP

    • The request includes use of leukocyte-rich platelet-rich plasma (LR-PRP).LR-PRP

      Marked approved after RN review. One meta-analysis of randomized controlled trials was highly positive when highly cellular LR-PRP was used.

    Lateral epicondylitis without LR-PRP

    • The request is without use of LR-PRP.No LR-PRP

      Marked for physician review. The broader evidence is inconsistent across varied controls and treatment arms.

    Rotator cuff injury subtype review

    Rotator cuff injuries are separated by clinical subtype.

    Rotator cuff tendinopathy or partial tears

    • The request is for rotator cuff tendinopathy or a partial tear.

      Marked approved after RN review. A meta-analysis found PRP to be a viable conservative alternative to corticosteroid injection, with comparable or improved pain and functional outcomes.

    All other rotator cuff tears

    • The request is for a rotator cuff tear other than tendinopathy or a partial tear.

      Marked experimental/investigational and denied as not a covered benefit.

    Achilles rupture is classified as experimental/investigational. The guideline indicates that surgical treatment is required for Achilles tendon ruptures; PRP utilization for this indication is therefore not a covered benefit.

    Surgical ACL reconstruction with PRP is classified as experimental/investigational. Systematic reviews found no beneficial effects from intraoperative PRP on clinical outcomes, bone-graft integration, or prevention of a bony tunnel; this utilization is not a covered benefit.

    PRP for meniscal tears without repair is classified as experimental/investigational. The guideline notes that available studies are few and small; this utilization is not a covered benefit.

    PRP for rotator cuff tears other than tendinopathy and partial tears is classified as experimental/investigational and is not a covered benefit.

    Codes Subject to Evaluation

    Codes subject to evaluation prior to paymentmixed
    0232TPlatelet-rich plasma injection procedure code subject to evaluation prior to payment
    G0460Platelet-rich plasma injection procedure code subject to evaluation prior to payment
    G0465Platelet-rich plasma injection procedure code subject to evaluation prior to payment
    P9020Platelet-rich plasma-related billing code subject to evaluation prior to payment

    Provider and Billing Actions

    Prior Authorization

    Prepayment Evaluation Required

    PRP billed under the listed CPT/HCPCS codes is subject to evaluation before payment is made.

    • Codes: 0232T, G0460, G0465, and P9020
    Prior Authorization

    Physician Review for Unlisted Use

    Utilization of PRP that is not listed in the guideline grid requires physician review before the service can be evaluated for payment.

    Documentation Required

    Accurate Claims and Medical Records Required

    Providers are responsible for submitting accurate claims and must provide supporting documentation, including provider records, when Wellfleet requests it.

    Documentation Required

    Identify the Diagnosis or Procedure

    Submit documentation that identifies the diagnosis or procedure so the PRP utilization can be matched to the applicable guideline grid.

    Denial Risk

    Experimental or Investigational Use

    PRP utilization determined to be experimental or investigational is denied because it is not a covered benefit.

    Denial Risk

    Unlisted Utilization May Not Be Paid Without Review

    Any PRP utilization not listed in the guideline grid must undergo physician review. Payment may not be made when the required review cannot be completed.

    Denial Risk

    Insufficient Claim Documentation

    Failure to submit accurate claim information or supporting documentation requested by Wellfleet may result in denial or delay of payment.

    Clinical Background

    Platelet-rich plasma (PRP) is used across a range of orthopedic and musculoskeletal conditions involving tendons, ligaments, muscles, cartilage, and joints. Because the evidence varies by diagnosis, treatment setting, PRP formulation, and comparator, the guideline evaluates utilization by specific diagnosis or procedure. Certain indications have limited or inconsistent evidence and are classified as experimental/investigational or require physician review.

    Definitions and Evaluation Outcomes

    Evaluation outcomes
    Supporting InformationEvidence or clinical information is provided.
    Appr.Approval after review by an RN.
    ReferReferral for physician review.
    LR-PRP
    LR-PRPLeukocyte-rich platelet-rich plasma.
    PRP
    PRPPlatelet-rich plasma.
    Policy Summary
    PayerWellfleet
    PolicyPlatelet-Rich Plasma Injections
    Policy CodePolicy GL-019
    Change TypeNo material change
    Effective DateNov 1, 2025
    Next Review DateSep 1, 2026
    Key ActionSubmit PRP claims under codes 0232T, G0460, G0465, or P9020 for evaluation before payment.
    SourceLink
    On This Page
    Coverage CriteriaCodes Subject to EvaluationProvider and Billing ActionsClinical BackgroundDefinitions and Evaluation Outcomes
    Lateral epicondylitis where the grid marks experimental/investigational utilization — experimental, investigational, or unproven.

    The formulation-specific entries are addressed separately in the lateral epicondylitis review.

  1. Meniscal tears without repair — experimental, investigational, or unproven.

    The grid states that few, small studies are available.

  2. Plantar fasciitis where the grid marks the experimental/investigational entry — experimental, investigational, or unproven.

    The evidence is described as conflicting and low quality, with marginal or limited benefit.

  3. Rotator cuff tears other than tendinopathy and partial tears — experimental, investigational, or unproven.

    This utilization is denied as not a covered benefit.